Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression
Danya Muilwijk, Eyleen de Poel, Peter van Mourik, Sylvia W.F. Suen, Annelotte M. Vonk, Jesse E. Brunsveld, Evelien Kruisselbrink, Hugo Oppelaar, Marne C. Hagemeijer, Gitte Berkers, Karin M. de Winter‐de Groot, Sabine Heida-Michel, S.R. Jans, H. van Panhuis, Menno M. van der Eerden, Renske van der Meer, Jolt Roukema, Edward Dompeling, Els J.M. Weersink, Gerard H. Koppelman, Robert G.J. Vries, Domenique D. Zomer-van Ommen, Marinus J.C. Eijkemans, Cornelis K. van der Ent, Jeffrey M. Beekman
Abstract
Rationale Cystic fibrosis (CF) is a monogenic life-shortening disease associated with highly variable individual disease progression which is difficult to predict. Here we assessed the association of forskolin-induced swelling (FIS) of patient-derived organoids with long-term CF disease progression in multiple organs and compared FIS with the golden standard biomarker sweat chloride concentration (SCC). Methods We retrieved 9-year longitudinal clinical data from the Dutch CF Registry of 173 people with mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene. Individual CFTR function was defined by FIS, measured as the relative size increase of intestinal organoids after stimulation with 0.8 µM forskolin, quantified as area under the curve (AUC). We used linear mixed-effect models and multivariable logistic regression to estimate the association of FIS with long-term forced expiratory volume in 1 s % predicted (FEV 1 pp) decline and development of pancreatic insufficiency, CF-related liver disease and diabetes. Within these models, FIS was compared with SCC. Results FIS was strongly associated with longitudinal changes of lung function, with an estimated difference in annual FEV 1 pp decline of 0.32% (95% CI 0.11–0.54%; p=0.004) per 1000-point change in AUC. Moreover, increasing FIS levels were associated with lower odds of developing pancreatic insufficiency (adjusted OR 0.18, 95% CI 0.07–0.46; p<0.001), CF-related liver disease (adjusted OR 0.18, 95% CI 0.06–0.54; p=0.002) and diabetes (adjusted OR 0.34, 95% CI 0.12–0.97; p=0.044). These associations were absent for SCC. Conclusion This study exemplifies the prognostic value of a patient-derived organoid-based biomarker within a clinical setting, which is especially important for people carrying rare CFTR mutations with unclear clinical consequences.